Neurotrek is developing U+™, the first targeted, non-invasive neuromodulation technology to improve mental health and well-being. The company is a California-based venture, backed by top-tier venture capital investors. Neurotrek completed a Series A financing in September, 2011 and a Series B financing in March, 2013. The company is engaged in early-stage development of U+™. In our Boston and Roanoke locations, we are developing both consumer-grade and clinical-grade products based on our core technology.